Commitments And Contingencies (Narrative) (Details) $ in Thousands	1 Months Ended							3 Months Ended	12 Months Ended	13 Months Ended
	Oct. 31, 2016 case	Oct. 31, 2015 motion	Aug. 31, 2015	Sep. 30, 2013 company	Feb. 28, 2013	Jan. 31, 2013	Jan. 31, 2012 study_order	Mar. 31, 2017 USD ($) case	Dec. 31, 2012 patent	Oct. 30, 2013	May 02, 2017 case	Dec. 31, 2016 USD ($)
Loss Contingencies [Line Items]
Reserve for loss contingencies								$ 758,700
Current portion of legal settlement accrual								758,693				$ 1,015,932
Vaginal mesh cases
Loss Contingencies [Line Items]
Current portion of legal settlement accrual								714,400
Testosterone Cases | Subsequent Event
Loss Contingencies [Line Items]
Pending claims, number | case											1,260
Unapproved Drug Litigation
Loss Contingencies [Line Items]
Number of additional pharmaceutical companies named in petitions (over 50) | company				50
Opana
Loss Contingencies [Line Items]
Lawsuits filed | case	2
Claim dismissal period	10 years
Gain Contingencies [Line Items]
Lawsuit filing period										45 days
Stay of approval period, Hatch-Waxman Act										30 months
Paragraph IV Certification on Fortesta Gel
Gain Contingencies [Line Items]
Lawsuit filing period						45 days
Stay of approval period, Hatch-Waxman Act					30 months
Judicial Ruling | Opana
Gain Contingencies [Line Items]
Number of patents found infringed upon | patent									2
Period for generic product to be withdrawn		60 days	60 days
Number of post-trial motions | motion		2
AMS | Vaginal mesh cases
Loss Contingencies [Line Items]
Product liability accrual, period expense								$ 714,400
Number of class-wide post-market study orders placed on hold by the FDA | study_order							16
Number of active class-wide post-market study orders | study_order							3
Loss contingency, claims settled, number | case								49,000
Settlement amount								$ 2,800,000
Lawsuits filed | case								10,500